| First Author | Wijesekara N | Year | 2017 |
| Journal | FASEB J | Volume | 31 |
| Issue | 12 | Pages | 5409-5418 |
| PubMed ID | 28808140 | Mgi Jnum | J:256411 |
| Mgi Id | MGI:6108507 | Doi | 10.1096/fj.201700431R |
| Citation | Wijesekara N, et al. (2017) Amyloid-beta and islet amyloid pathologies link Alzheimer's disease and type 2 diabetes in a transgenic model. FASEB J 31(12):5409-5418 |
| abstractText | Alzheimer''s disease (AD) and type 2 diabetes (T2D) present a significant risk to each other. AD and T2D are characterized by deposition of cerebral amyloid-beta (Abeta) and pancreatic human islet amyloid polypeptide (hIAPP), respectively. We investigated the role of amyloidogenic proteins in the interplay between these diseases. A novel double transgenic mouse model combining T2D and AD was generated and characterized. AD-related amyloid transgenic mice coexpressing hIAPP displayed peripheral insulin resistance, hyperglycemia, and glucose intolerance. Abeta and IAPP amyloid co-deposition increased tau phosphorylation, and a reduction in pancreatic beta-cell mass was detected in islets. Increased brain Abeta deposition and tau phosphorylation and reduced insulin levels and signaling were accompanied by extensive synaptic loss and decreased neuronal counts. Abeta immunization rescued the peripheral insulin resistance and hyperglycemia, suggesting a role for Abeta in T2D pathogenesis for individuals predisposed to AD. These findings demonstrate that Abeta and IAPP are key factors in the overlapping pathologies of AD and T2D.-Wijesekara, N., Ahrens, R., Sabale, M., Wu, L., Ha, K., Verdile, G., Fraser, P. E. Amyloid-beta and islet amyloid pathologies link Alzheimer''s disease and type 2 diabetes in a transgenic model. |
